These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23964940)

  • 41. Etrolizumab for ulcerative colitis: the new kid on the block?
    Makker J; Hommes DW
    Expert Opin Biol Ther; 2016; 16(4):567-72. PubMed ID: 26914639
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
    Shen H; Lipka S; Katz S
    J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
    [No Abstract]   [Full Text] [Related]  

  • 43. [Immunosuppression in inflammatory bowel disease: When, how and how long?].
    Gross V
    Dtsch Med Wochenschr; 2012 Sep; 137(37):1803-5. PubMed ID: 22956222
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Postoperative complications of pediatric patients with inflammatory bowel disease treated with vedolizumab.
    Zimmerman LA; Zalieckas JM; Shamberger RC; Bousvaros A
    J Pediatr Surg; 2018 Jul; 53(7):1330-1333. PubMed ID: 29370898
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents.
    Molander P; af Björkesten CG; Mustonen H; Haapamäki J; Vauhkonen M; Kolho KL; Färkkilä M; Sipponen T
    Inflamm Bowel Dis; 2012 Nov; 18(11):2011-7. PubMed ID: 22223566
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metastatic Crohn disease improving with vedolizumab.
    Costa Blasco M; McFeely O; Doyle C; Wolinska A; Andrawis M; Murphy L; Beatty P; O'Mahony S; Hackett C
    Br J Dermatol; 2023 Jul; 189(2):e35. PubMed ID: 36951142
    [No Abstract]   [Full Text] [Related]  

  • 47. VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY.
    Perin RL; Damião AOMC; Flores C; Ludvig JC; Magro DO; Miranda EF; Moraes AC; Nones RB; Teixeira FV; Zeroncio M; Kotze PG
    Arq Gastroenterol; 2019; 56(3):312-317. PubMed ID: 31633731
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biologic Therapeutic Drug Monitoring in Australia.
    J Connor S
    J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():8-9. PubMed ID: 26990573
    [No Abstract]   [Full Text] [Related]  

  • 49. Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting.
    Afzali A; Ogden K; Friedman ML; Chao J; Wang A
    J Med Econ; 2017 Apr; 20(4):409-422. PubMed ID: 28112566
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of biologics in the treatment of patients with inflammatory bowel disease.
    Selinger CP; Carbery I; Al-Asiry J
    Br J Hosp Med (Lond); 2018 Dec; 79(12):686-693. PubMed ID: 30526103
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PF-00547659 for the treatment of Crohn's disease and ulcerative colitis.
    Allocca M; Gilardi D; Fiorino G; Furfaro F; Argollo M; Peyrin-Biroulet L; Danese S
    Expert Opin Investig Drugs; 2018 Jul; 27(7):623-629. PubMed ID: 29985060
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inflammatory bowel disease: short- and long-term treatments.
    Bickston SJ; Cominelli F
    Dis Mon; 1998 Apr; 44(4):144-72. PubMed ID: 9580743
    [No Abstract]   [Full Text] [Related]  

  • 53. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
    Lee TW; Fedorak RN
    Gastroenterol Clin North Am; 2010 Sep; 39(3):543-57. PubMed ID: 20951917
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Etrolizumab in ulcerative colitis: tightening leukocyte traffic control in the inflamed mucosa.
    Fiorino G; Danese S
    Gastroenterology; 2014 Dec; 147(6):1433-5. PubMed ID: 25457851
    [No Abstract]   [Full Text] [Related]  

  • 55. Effectiveness of infliximab in Brazilian children and adolescents with Crohn disease and ulcerative colitis according to clinical manifestations, activity indices of inflammatory bowel disease, and corticosteroid use.
    Tiemi J; Komati S; Sdepanian VL
    J Pediatr Gastroenterol Nutr; 2010 Jun; 50(6):628-33. PubMed ID: 20386321
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vedolizumab for the treatment of ulcerative colitis.
    Stallmach A; Schmidt C; Teich N
    Expert Rev Gastroenterol Hepatol; 2016; 10(2):165-75. PubMed ID: 26588993
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.
    Rosario M; Dirks NL; Gastonguay MR; Fasanmade AA; Wyant T; Parikh A; Sandborn WJ; Feagan BG; Reinisch W; Fox I
    Aliment Pharmacol Ther; 2015 Jul; 42(2):188-202. PubMed ID: 25996351
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.
    Smith MA; Mohammad RA
    Ann Pharmacother; 2014 Dec; 48(12):1629-35. PubMed ID: 25186623
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.
    Tursi A; Elisei W; Picchio M; Giorgetti G; Brandimarte G
    Dig Dis Sci; 2015 May; 60(5):1406-13. PubMed ID: 25445163
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study.
    Baumgart DC; Bokemeyer B; Drabik A; Stallmach A; Schreiber S;
    Aliment Pharmacol Ther; 2016 May; 43(10):1090-102. PubMed ID: 27038247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.